Scholarlink

Introduction <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem disorder closely linked to cardiovascular morbidity. While its association with coronary artery disease (CAD) is well established, evidence regarding its relationship with systemic atherosclerosis remains limited. This study aimed to investigate the association between non-invasive MASLD markers and atherosclerotic burden across multiple vascular territories.</p> Methods <p>We conducted a retrospective single-center study including 56 patients who underwent coronary angiography, vascular ultrasonography (carotid arteries, lower limb arteries, abdominal aorta), and transient liver elastography (FibroScan<sup>®</sup>) between 2023 and 2025. Liver parameters included liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and non-invasive scores: FibroScan-AST (FAST), Fibrosis-4 Index (FIB-4), and advanced generative liver evaluation 3 + (AGILE 3 +). Atherosclerotic disease burden was classified as disease-free (0 vascular sites affected), focal (1 site), intermediate (2–3 sites), or generalized (4–6 sites) based on the evaluation of six vascular territories and was further quantified using SYNTAX I and Gensini scores (CAD), NASCET method (carotid artery stenosis, CAS), Bollinger score (peripheral artery disease, PAD), and Kronzon score (aortic sclerosis, AS).</p> Results <p>Liver parameters and scores correlated significantly with greater atherosclerotic burden. Patients with atherosclerotic cardiovascular disease (ASCVD) (<i>n</i> = 45) demonstrated significantly higher liver stiffness (LSM: 5.8 [4.2–7.5] vs. 4.5 [3.0–5.1] kPa; <i>p</i> = 0.0472) and steatosis (CAP: 253 [220.5–290.5] vs. 210 [184–251.0] dB/m; <i>p</i> = 0.0097) compared to those without ASCVD. Non-invasive liver scores were significantly elevated in ASCVD patients and variably associated with vascular burden and severity scores after adjustment for sex and age: AGILE 3 + correlated with SYNTAX I (<i>β</i> = 0.008446, <i>p</i> = 0.0045), Gensini (<i>β</i> = 0.0024, <i>p</i> = 0.049), and Kronzon score (<i>β</i> = 0.06413, <i>p</i> = 0.0274). FAST correlated with the Kronzon score (<i>β</i> = 0.04011, <i>p</i> = 0.0064). Hepatic steatosis (CAP ≥ 248&#xa0;dB/m) or fibrosis (LSM ≥ 6.5&#xa0;kPa) was present in 73.3% of ASCVD patients vs. 36.4% of No ASCVD (<i>p</i> = 0.0325).</p> Conclusion <p>Non-invasive hepatic markers—particularly the AGILE 3 + score—demonstrated significant associations with the presence and extent of systemic atherosclerosis. These findings support a “liver–vascular axis” and highlight the potential utility of liver-derived scores as surrogate markers of cardiovascular risk in patients with MASLD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of metabolic dysfunction-associated steatotic liver disease markers and atherosclerotic disease burden

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Mohamad Amer Nashtar,
  • Obayda Azizy,
  • Jasmin Weninger,
  • Mustafa Özcürümez,
  • Eda Kaya,
  • Antonios Katsounas,
  • Ali Canbay,
  • Polykarpos Christos Patsalis,
  • Martin Steinmetz

摘要

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem disorder closely linked to cardiovascular morbidity. While its association with coronary artery disease (CAD) is well established, evidence regarding its relationship with systemic atherosclerosis remains limited. This study aimed to investigate the association between non-invasive MASLD markers and atherosclerotic burden across multiple vascular territories.

Methods

We conducted a retrospective single-center study including 56 patients who underwent coronary angiography, vascular ultrasonography (carotid arteries, lower limb arteries, abdominal aorta), and transient liver elastography (FibroScan®) between 2023 and 2025. Liver parameters included liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and non-invasive scores: FibroScan-AST (FAST), Fibrosis-4 Index (FIB-4), and advanced generative liver evaluation 3 + (AGILE 3 +). Atherosclerotic disease burden was classified as disease-free (0 vascular sites affected), focal (1 site), intermediate (2–3 sites), or generalized (4–6 sites) based on the evaluation of six vascular territories and was further quantified using SYNTAX I and Gensini scores (CAD), NASCET method (carotid artery stenosis, CAS), Bollinger score (peripheral artery disease, PAD), and Kronzon score (aortic sclerosis, AS).

Results

Liver parameters and scores correlated significantly with greater atherosclerotic burden. Patients with atherosclerotic cardiovascular disease (ASCVD) (n = 45) demonstrated significantly higher liver stiffness (LSM: 5.8 [4.2–7.5] vs. 4.5 [3.0–5.1] kPa; p = 0.0472) and steatosis (CAP: 253 [220.5–290.5] vs. 210 [184–251.0] dB/m; p = 0.0097) compared to those without ASCVD. Non-invasive liver scores were significantly elevated in ASCVD patients and variably associated with vascular burden and severity scores after adjustment for sex and age: AGILE 3 + correlated with SYNTAX I (β = 0.008446, p = 0.0045), Gensini (β = 0.0024, p = 0.049), and Kronzon score (β = 0.06413, p = 0.0274). FAST correlated with the Kronzon score (β = 0.04011, p = 0.0064). Hepatic steatosis (CAP ≥ 248 dB/m) or fibrosis (LSM ≥ 6.5 kPa) was present in 73.3% of ASCVD patients vs. 36.4% of No ASCVD (p = 0.0325).

Conclusion

Non-invasive hepatic markers—particularly the AGILE 3 + score—demonstrated significant associations with the presence and extent of systemic atherosclerosis. These findings support a “liver–vascular axis” and highlight the potential utility of liver-derived scores as surrogate markers of cardiovascular risk in patients with MASLD.